Subtherapeutic concentrations of first-line anti-TB drugs in South African children treated according to current guidelines: The PHATISA study

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 4, 2014, Pages 1115-1123

  Hiruy, Hiwot ^a   Rogers, Zoe ^b   Mbowane, Chris ^c   Adamson, John ^b   Ngotho, Lihle ^b   Karim, Farina ^b   Gumbo, Tawanda ^d   Bishai, William ^a,b,e   Jeena, Prakash ^c  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b AFRICA HEALTH RESEARCH INSTITUTE   (South Africa)

^c UNIVERSITY OF KWAZULU NATAL   (South Africa)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

Anti tuberculosis drug pharmacokinetics; Paediatric pharmacokinetics; Paediatric tuberculosis

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; FEMALE; HUMAN; INFANT; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MALE; MAXIMUM PLASMA CONCENTRATION; OBSERVATIONAL STUDY; PRACTICE GUIDELINE; PROSPECTIVE STUDY; SCHOOL CHILD; SOUTH AFRICA; TREATMENT DURATION; TUBERCULOSIS; BLOOD ANALYSIS; DRUG COMBINATION; PRESCHOOL CHILD; PROCEDURES; TIME;

ANTITUBERCULAR AGENTS; BLOOD CHEMICAL ANALYSIS; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFANT; MALE; PROSPECTIVE STUDIES; SOUTH AFRICA; TIME FACTORS; TUBERCULOSIS;

EID: 84926477447     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku478     Document Type: Article

References (38)

1. WHO. WHO Report 2011: Global Tuberculosis Control. 2011. http://www. who.int/tb/country/en/.
2. Dheda K, Gumbo T, Gandhi NR et al. Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis. Lancet Respir Med 2014; 2: 321-38.
3. Drusano GL, Forrest A, Yuen G et al. Optimal sampling theory: effect of error in a nominal parameter value on bias and precision of parameter estimation. J Clin Pharmacol 1994; 34: 967-74.
4. Reed MD. Optimal sampling theory: an overview of its application to pharmacokinetic studies in infants and children. Pediatrics 1999; 104: 627-32.
5. Tam VH, Preston SL, Drusano GL. Optimal sampling schedule design for populations of patients. Antimicrob Agents Chemother 2003; 47: 2888-91.
6. Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 2002; 62: 2169-83.
7. WHO. Rapid Advice: Treatment of Tuberculosis in Children. 2010. http://whqlibdoc.who.int/publications/2010/9789241500449_eng.pdf?ua=1.
8. McIlleron H, Wash P, Burger A et al. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob Agents Chemother 2006; 50: 1170-7.
9. Narita M, Hisada M, Thimmappa B et al. Tuberculosis recurrence: multivariate analysis of serum levels of tuberculosis drugs, human immunodeficiency virus status, and other risk factors. Clin Infect Dis 2001; 32: 515-7.
10. Burhan E, Ruesen C, Ruslami R et al. Isoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients. Antimicrob Agents Chemother 2013; 57: 3614-9.
11. Srivastava S, Pasipanodya JG, Meek C et al. Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability. J Infect Dis 2011; 204: 1951-9.
12. Pasipanodya JG, McIlleron H, Burger A et al. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis 2013; 208: 1464-73.
13. Pasipanodya JG, Srivastava S, Gumbo T. Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy. Clin Infect Dis 2012; 55: 169-77.
14. Gumbo T, Louie A, Deziel MR et al. Selection of amoxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J Infect Dis 2004; 190: 1642-51.
15. Gumbo T, Louie A, Deziel MR et al. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob Agents Chemother 2007; 51: 3781-8.
16. Gumbo T, Louie A, Liu W et al. Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations. Antimicrob Agents Chemother 2007; 51: 2329-36.
17. Gumbo T, Siyambalapitiyage Dona CS, Meek C et al. Pharmacokineticspharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs. Antimicrob Agents Chemother 2009; 53: 3197-204.
18. Srivastava S, Musuka S, Sherman C et al. Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol. J Infect Dis 2010; 201: 1225-31.
19. Pasipanodya JG, Gumbo T. A new evolutionary and pharmacokineticpharmacodynamic scenario for rapid emergence of resistance to single and multiple anti-tuberculosis drugs. Curr Opin Pharmacol 2011; 11: 457-63.
20. Schmalstieg AM, Srivastava S, Belkaya S et al. The antibiotic resistance arrow of time: efflux pump induction is a general first step in the evolution of mycobacterial drug resistance. Antimicrob Agents Chemother 2012; 56: 4806-15.
21. Pasipanodya JG, Gumbo T. A meta-analysis of self-administered versus directly observed therapy effect on microbiologic failure, relapse, and acquired drug resistance in tuberculosis patients. Clin Infect Dis 2013; 57: 21-31.
22. Pasipanodya J, Gumbo T. An oracle: antituberculosis pharmacokinetics- pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future. Antimicrob Agents Chemother 2011; 55: 24-34.
23. Jayaram R, Gaonkar S, Kaur P et al. Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 2003; 47: 2118-24.
24. Jayaram R, Shandil RK, Gaonkar S et al. Isoniazid pharmacokineticspharmacodynamics in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 2004; 48: 2951-7.
25. Chigutsa E, Pasipanodya JG, Sirgel FA et al. The impact of non-linear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis. Antimicrob Agents Chemother 2014; doi:10.1128/AAC.03931-14.
26. Cundall DB. The diagnosis of pulmonary tuberculosis in malnourished Kenyan children. Ann Trop Paediatr 1986; 6: 249-55.
27. Wang J, Endrenyi L. A computationally efficient approach for the design of population pharmacokinetic studies. J Pharmacokinet Biopharm 1992; 20: 279-94.
28. Song SH, Jun SH, Park KU et al. Simultaneous determination of first-line anti-tuberculosis drugs and their major metabolic ratios by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2007; 21: 1331-8.
29. D'Argenio DZ, Schumitzky A, Wang X. ADAPT 5 User's Guide:Pharmacokinetic/Pharmacodynamic Systems Analysis Software. Los Angeles, CA: Biomedical Simulations Resource, 2009.
30. McIlleron H, Willemse M, Werely CJ et al. Isoniazid plasma concentrations in a cohort of South African children with tuberculosis: implications for international pediatric dosing guidelines. Clin Infect Dis 2009; 48: 1547-53.
31. Newton SM, Brent AJ, Anderson S et al. Paediatric tuberculosis. Lancet Infect Dis 2008; 8: 498-510.
32. Thee S, Seddon JA, Donald PR et al. Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations. Antimicrob Agents Chemother 2011; 55: 5560-7.
33. Ramachandran G, Hemanth Kumar AK, Bhavani PK et al. Age, nutritional status and INH acetylator status affect pharmacokinetics of antituberculosis drugs in children. Int J Tuberc Lung Dis 2013; 17: 800-6.
34. Chigutsa E, Meredith S, Wiesner L et al. Population pharmacokinetics and pharmacodynamics of ofloxacin in South African patients with multidrug-resistant tuberculosis. Antimicrob Agents Chemother 2012; 56: 3857-63.
35. West GB, Brown JH, Enquist BJ. A general model for the origin of allometric scaling laws in biology. Science 1997; 276: 122-6.
36. West GB, Brown JH, Enquist BJ. The fourth dimension of life: fractal geometry and allometric scaling of organisms. Science 1999; 284: 1677-9.
37. West GB, Savage VM, Gillooly J et al. Physiology: why does metabolic rate scale with body size? Nature 2003; 421: 713.
38. HopeWW, Seibel NL, Schwartz CL et al. Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing. Antimicrob Agents Chemother 2007; 51: 3714-9.